Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide Maintenance in DSRCT and Synovial Sarcoma
NCT06456359Phase 2Recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Dec 2024
- Primary completion
- Oct 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in desmoplastic small round cell tumor (DSRCT) and synovial sarcoma (SS), sponsored by Heidelberg University Hospital. Primary endpoint: Progression-Free Survival at 4 years. Started Dec 2024; status: recruiting.
02
Drugs
pasireotide LAR
03
Conditions
desmoplastic small round cell tumor (DSRCT)synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT06456359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456359.